Centchroman
Ormeloxifene
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Oral
-
Intended Duration:
- Short-Acting
- Development Stage: Phase IV
- Developer(s)/researcher(s): King George's Medical University, India Health Action Trust, Central Drug Research Institute, India, HLL Lifecare Limited
Details
- API: Ormeloxifene
- Target: Estrogen Receptor
-
Mechanism of Action:
- Ovulation Delay
- Regimen: 1 Pill/Week
- MPT: Not Potential MPT
- Promising Attributes: Centchroman may be a viable contraceptive option for users resistant to or unable to use hormonal contraceptive pills, should efficacy be proven through high quality evaluation.
Product Status
Product is actively marketed in India. Contraceptive efficacy analysis, to a higher degree of scientific rigor than previous evaluation, is underway with support from the Gates Foundation.
History
1980s: The Central Drug Research Institute Lucknow synthesizes Centchroman and develops a weekly pill intended to disrupt the timing of ovulation and the thickening of endometrial tissue to prevent implantation
1991-1995: Product is introduced in Delhi by CDRI in partnership with local government. It's later licensed to commercial partners and added to the National Family Welfare Programme.
2018: National government initiates free provision of product through public family planning service delivery channels
2024: Funding from the Gates Foundation supports efficacy analysis